Intuitive Surgical, Inc. (ISRG) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates in one reportable segment, managing its business on a consolidated basis. As of September 30, 2025, the company had an installed base of approximately 10,763 da Vinci systems and 954 Ion systems.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $2,505.1 | $2,038.1 | $7,198.5 | $5,938.6 |
| Gross Profit | $1,662.4 | $1,373.9 | $4,738.0 | $3,992.0 |
| Gross Margin | 66.4% | 67.4% | 65.8% | 67.2% |
| Operating Income | $759.7 | $577.3 | $2,081.2 | $1,614.0 |
| Net Income (Attributable to ISRG) | $704.4 | $565.1 | $2,061.2 | $1,636.9 |
| Diluted EPS | $1.95 | $1.56 | $5.67 | $4.53 |
| Cash & Investments | $8,432.5 | $8,832.4 | $8,432.5 | $8,832.4 |
| Operating Cash Flow (9M) | $2,138.0 | $1,592.4 | $2,138.0 | $1,592.4 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23% year-over-year (YoY) in Q3 2025, driven by a 20% increase in instruments and accessories revenue and a 33% increase in systems revenue.
- Procedure Volume: da Vinci procedures grew 19% to approximately 797,000 in Q3 2025. Ion procedures grew 52% to approximately 37,900.
- System Placements: The company placed 427 da Vinci systems in Q3 2025 (up from 379 in Q3 2024), including 240 da Vinci 5 systems. Ion placements were 50 units.
- Margin Compression: Gross margin decreased to 66.4% from 67.4% in the prior year quarter. Management attributed this primarily to the impact of tariffs, higher costs associated with the phased launch of the da Vinci 5 system, and incremental fixed overhead costs.
- Share Repurchases: The company repurchased 4.0 million shares for $1.92 billion in Q3 2025. Approximately $1.9 billion remains authorized under the repurchase program.
Guidance, Outlook, and Risks
- Tariff Impact: New U.S. tariffs imposed in 2025 on imports from Mexico, Germany, and China increased cost of revenues by approximately $22 million in Q3 and $37 million YTD. Management expects these costs to continue increasing into Q4 2025.
- Product Launches: The company is in the midst of a phased launch of the da Vinci 5 surgical system globally. Regulatory clearances were obtained in Japan (June 2025) and Europe (July 2025). The da Vinci SP system continues to expand indications.
- Capital Expenditures: Expected to range between $625 million and $675 million for 2025, primarily for facilities-related investments to scale manufacturing.
- Legal Contingencies: The company faces ongoing product liability litigation and antitrust claims (e.g., Surgical Instrument Service Company, Inc. and class actions regarding instrument repair). While the company disputes these allegations, outcomes remain uncertain and could materially affect results.
- China Market: System demand in China has been adversely impacted by competition from domestic companies and government governance campaigns, though the full extent of the impact remains uncertain.
Investor Verification Checklist
- Tariff Exposure: Verify the specific impact of new tariffs on the cost of raw materials and finished goods, particularly regarding imports from Mexico and Germany.
- da Vinci 5 Adoption: Monitor the rate of trade-ins of fourth-generation systems for the da Vinci 5 and the associated revenue recognition timing.
- China Quotas: Track the utilization of the 2023 quota for surgical robots in China and any new provincial pricing limits on robotic procedures.
- Antitrust Litigation: Review the status of the "In Re: da Vinci Surgical Robot Antitrust Litigation" and the appeal of the SIS antitrust case, as these could impact service revenue models.
- Inventory Levels: Note the significant increase in inventory ($1.78 billion vs $1.49 billion prior year), driven by supply chain mitigation and leasing business expansion.